• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014

    Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014

  2. Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)

    Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)

  3. UPDATE: 14 stocks loved by top-performing fund -2-

    UPDATE: 14 stocks loved by top-performing fund -2-

  4. UPDATE: 14 stocks loved by top-performing fund managers

    UPDATE: 14 stocks loved by top-performing fund managers

  5. UPDATE: 14 stocks loved by top-performing fund -3-

    UPDATE: 14 stocks loved by top-performing fund -3-

  6. Research and Markets: Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec , Merck Serono, Novartis & Teva Pharmaceutical

    Research and Markets: Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec , Merck Serono, Novartis & Teva Pharmaceutical

  7. Corporate Social Responsibility Weekly Recap (September 17, 2014 – September 24, 2014)

    Corporate Social Responsibility Weekly Recap (September 17, 2014 – September 24, 2014)

  8. Acorda Therapeutics to Acquire Civitas Therapeutics

    Acorda Therapeutics to Acquire Civitas Therapeutics

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.